Protocol Ledger

NCT04996875 · Phase II · RECRUITING

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Interventional Phase II clinical trial protocol NCT04996875 sponsored by Cogent Biosciences in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-11-09 Enrollment: 140 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04996875
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)140 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04996875
Protocol FieldVerified Registry Value
NCT IdentifierNCT04996875
Consolidated Lead SponsorCogent Biosciences
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment140 participants (ESTIMATED)
Registered Start Date2021-11-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI